{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T04:51:20Z","timestamp":1788411080253,"version":"build-2803163510"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T00:00:00Z","timestamp":1715904000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Ophthalmol."],"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p>To evaluate percutaneous triamcinolone (TA) injection efficacy in treating upper eyelid retraction (UER) for Australian thyroid eye disease (TED) patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We conducted a retrospective analysis across 8 years and multiple diverse Australian centres identified UER patients who received TA injections. A single operator administered 40mg\/1ml TA through upper eyelid skin. Assessments at 4-6 weeks and subsequent eyelid measurements gauged treatment response and complications.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>24 patients and 25 eyelids were included in the study. 91.6% were female, mean age 40.8 \u00b1 10.3 years with mean follow-up of 17.5 months (\u00b1 18.5). Pre-treatment MRD1 was 6.2mm \u00b1 1.4, and we observed a mean improvement of 2.2mm from pre-treatment to post-treatment (p&amp;lt;0.001). The mean UER measurement before treatment (defined as MRD1 - 4.0mm) was 3.0mm \u00b1 1.3 (range, 0-6mm). After treatment, the mean UER measurement was -0.1mm. Quality of life (QOL) assessment improved significantly, from pre-treatment score of 4.13 \u00b1 2.4 to post-treatment 8.0 \u00b11.7 (p&amp;lt;0.001).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Percutaneous injection of TA is an effective and safe treatment option for UER in patients with TED. This technique can be performed without upper eyelid eversion, which makes it more tolerable for patients and less complex for the operator compared to the transconjunctival injection approach. Our results show a significant improvement in MRD1 and UER, as well as patient QOL. Moreover, we found a low rate of complications (4.2% induced ptosis) and no cases of raised intraocular pressure. Percutaneous TA injection can greatly reduce the need for eyelid lowering surgery in this patient population.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fopht.2024.1388197","type":"journal-article","created":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T08:28:41Z","timestamp":1715934521000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Percutaneous triamcinolone injection for upper eyelid retraction in thyroid eye disease"],"prefix":"10.3389","volume":"4","author":[{"given":"Shaun R.","family":"Parsons","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ario","family":"Wilson-Pogmore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy J.","family":"Sullivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,5,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9394(14)70276-4","article-title":"Clinical features of Graves\u2019 ophthalmopathy in an incidence cohort","volume":"121","author":"Bartley","year":"1996","journal-title":"Am J Ophthalmol"},{"key":"B2","article-title":"Upper eyelid retraction in Graves\u2019 ophthalmopathy: A new surgical technique and a study of the abnormal levator muscle","volume":"86","author":"Small","year":"1988","journal-title":"Trans Am Ophthalmol Soc"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3928\/1542-8877-19860401-04","article-title":"Lid retraction and levator aponeurosis defects in Graves\u2019 eye disease","volume":"17","author":"Frueh","year":"1986","journal-title":"Ophthalmic Surg"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.87.6.773","article-title":"Impact of smoking on the response to treatment of thyroid associated ophthalmopathy","volume":"87","author":"Eckstein","year":"2003","journal-title":"Br J Ophthalmol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.beem.2011.11.001","article-title":"Quality of life in Graves\u2019 ophthalmopathy","volume":"26","author":"Wiersinga","year":"2012","journal-title":"Best Pract Research: Clin Endocrinol Metab"},{"key":"B6","doi-asserted-by":"crossref","DOI":"10.1097\/IOP.0000000000001120","article-title":"Transconjunctival Triamcinolone Injection for Upper Lid Retraction in Thyroid Eye Disease-A New Injection Method","volume-title":"Ophthalmic Plastic and Reconstructive Surgery","author":"Young","year":"2018"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(89)32874-0","article-title":"Enlargement of levator palpebrae superioris muscle fivers in graves\u2019 Ophthalmopathy","volume":"96","author":"Small","year":"1989","journal-title":"Ophthalmology"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2018-313578","article-title":"Course of upper eyelid retraction in thyroid eye disease","volume":"104","author":"Lee","year":"2020","journal-title":"Br J Ophthalmology"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1097\/ICU.0b013e3283499433","article-title":"A review of surgical techniques to correct upper eyelid retraction associated with thyroid eye disease","volume":"22","author":"Kazim","year":"2011","journal-title":"Curr Opin Ophthalmol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(81)34996-3","article-title":"The aponeurotic approach to eyelid retraction","volume":"88","author":"Harvey","year":"1981","journal-title":"Ophthalmology"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2017-310695","article-title":"Non-surgical treatment for eyelid retraction in thyroid eye disease (TED)","volume":"102","author":"Grisolia","year":"2018","journal-title":"Br J Ophthalmol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1097\/PRS.0b013e3182362c63","article-title":"Cosmetic medicine: Facial resurfacing and injectables","volume":"129","author":"Nguyen","year":"2012","journal-title":"Plast Reconstr Surg"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-015-2957-7","article-title":"Fornix triamcinolone injection for thyroid orbitopathy","volume":"253","author":"Hamed-Azzam","year":"2015","journal-title":"Graefe\u2019s Arch Clin Exp Ophthalmology"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1097\/SCS.0b013e3182646043","article-title":"Subconjunctival injection of triamcinolone for the treatment of upper lid retraction associated with thyroid eye disease","volume":"23","author":"Lee","year":"2012","journal-title":"J Craniofacial Surg"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-012-2153-y","article-title":"Treatment of upper eyelid retraction related to thyroid-associated ophthalmopathy using subconjunctival triamcinolone injections","volume":"251","author":"Lee","year":"2013","journal-title":"Graefe\u2019s Arch Clin Exp Ophthalmol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcjo.2011.12.005","article-title":"Repeated triamcinolone acetonide injection in the treatment of upper-lid retraction in patients with thyroid-associated ophthalmopathy","volume":"47","author":"Xu","year":"2012","journal-title":"Can J Ophthalmology"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/sj.eye.6702933","article-title":"Subconjunctival injection of triamcinolone in the treatment of lid retraction of patients with thyroid eye disease: A case series","volume":"22","author":"Chee","year":"2008","journal-title":"Eye"},{"key":"B18","article-title":"Long-term effect of triamcinolone acetonide in the treatment of upper lid retraction with thyroid associated ophthalmopathy","volume":"11","author":"Xu","year":"2018","journal-title":"Int J Ophthalmol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.2147\/IMCRJ","article-title":"Clinical efficacy of transcutaneous triamcinolone acetonide injection for upper eyelid retraction and swelling in patients with thyroid eye disease","volume":"11","author":"Kozaki","year":"2018","journal-title":"Int Med Case Rep J"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1111\/ceo.12939","article-title":"Peri-levator palpebrae superioris triamcinolone injection for the treatment of thyroid eye disease-associated upper eyelid retraction","author":"Joos","year":"2017","journal-title":"Clin Exp Ophthalmol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1097\/01.iop.0000235499.34867.85","article-title":"VISA classification for graves orbitopathy","volume":"22","author":"Dolman","year":"2006","journal-title":"Ophthalmic Plast Reconstructive Surg"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1097\/00002341-200405000-00001","article-title":"Botulinum toxin type A for dysthyroid upper eyelid retraction","volume":"20","author":"Morgenstern","year":"2004","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"B23","doi-asserted-by":"crossref","DOI":"10.1034\/j.1600-0420.2001.790608.x","article-title":"Thyroid associated ophthalmopathy: Botulinum toxin A\u00a0in\u00a0the treatment of upper eyelid retraction - A pilot study","volume":"79","author":"Tr\u00e4isk","year":"2001","journal-title":"Acta Ophthalmol Scand"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3109\/01676830903324268","article-title":"Transcutaneous dysport injection for treatment of upper eyelid retraction associated with thyroid eye disease","volume":"29","author":"Salour","year":"2010","journal-title":"Orbit"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.88.1.75","article-title":"Assessing quality of life in Australian patients with Graves\u2019 ophthalmopathy","volume":"88","author":"Park","year":"2004","journal-title":"Br J Ophthalmology"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2012.07.003","article-title":"TSH receptor autoantibody immunoassay in patients with Graves\u2019 disease: Improvement of diagnostic accuracy over different generations of methods. Systematic review and meta-analysis","volume":"12","author":"Tozzoli","year":"2012","journal-title":"Autoimmun Rev"},{"key":"B27","doi-asserted-by":"crossref","DOI":"10.1007\/s40618-020-01353-y","article-title":"Correlation between serum anti-TSH receptor autoantibodies (TRAbs) and the clinical feature of Graves\u2019 orbitopathy","volume":"44","author":"Nicol\u00ec","year":"2021","journal-title":"J Endocrinol Invest"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1111\/cen.13908","article-title":"Thyrotrophin receptor antibody concentration and activity, several years after treatment for Graves\u2019 disease","volume":"90","author":"Nalla","year":"2019","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-07-0450","article-title":"TSH-receptor autoimmunity in Graves\u2019 disease after therapy with anti-thyroid drugs, surgery, or radioiodine: A 5-year prospective randomized study","volume":"158","author":"Laurberg","year":"2008","journal-title":"Eur J Endocrinol"},{"key":"B30","doi-asserted-by":"crossref","DOI":"10.4103\/ijo.IJO_2228_21","article-title":"Triamcinolone acetonide injection in the treatment of upper eyelid retraction in Graves\u2019 ophthalmopathy evaluated by 3.0 Tesla magnetic resonance imaging","volume":"70","author":"Duan","year":"2022","journal-title":"Indian J Ophthalmol"},{"key":"B31","article-title":"The MRI manifestations of the levator muscles in thyroid associated ophthalmopathy","volume":"23","author":"Ai","year":"2014","journal-title":"Ophthalmol China"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3389\/fopht.2023.1296092","article-title":"Orbital corticosteroid injections for the treatment of active thyroid eye disease","volume":"3","author":"Eid","year":"2024","journal-title":"Front Ophthalmol"}],"container-title":["Frontiers in Ophthalmology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fopht.2024.1388197\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,19]],"date-time":"2024-11-19T07:25:59Z","timestamp":1732001159000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fopht.2024.1388197\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,17]]},"references-count":32,"alternative-id":["10.3389\/fopht.2024.1388197"],"URL":"https:\/\/doi.org\/10.3389\/fopht.2024.1388197","relation":{},"ISSN":["2674-0826"],"issn-type":[{"value":"2674-0826","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,17]]},"article-number":"1388197"}}